Northwestern Mutual Wealth Management Co. Raises Stock Position in Invesco Biotechnology & Genome ETF $PBE

Northwestern Mutual Wealth Management Co. increased its stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 9,169.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 342,971 shares of the company’s stock after acquiring an additional 339,271 shares during the quarter. Northwestern Mutual Wealth Management Co. owned about 0.11% of Invesco Biotechnology & Genome ETF worth $28,175,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PBE. Comerica Bank increased its holdings in Invesco Biotechnology & Genome ETF by 86.2% in the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock worth $31,000 after acquiring an additional 175 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Invesco Biotechnology & Genome ETF by 74.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock worth $40,000 after acquiring an additional 245 shares in the last quarter. NewEdge Advisors LLC increased its holdings in Invesco Biotechnology & Genome ETF by 63.2% in the 3rd quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock worth $62,000 after acquiring an additional 342 shares in the last quarter. Blair William & Co. IL increased its holdings in Invesco Biotechnology & Genome ETF by 150.0% in the 3rd quarter. Blair William & Co. IL now owns 1,000 shares of the company’s stock worth $70,000 after acquiring an additional 600 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter worth $82,000.

Invesco Biotechnology & Genome ETF Stock Down 0.6%

Invesco Biotechnology & Genome ETF stock opened at $80.39 on Tuesday. Invesco Biotechnology & Genome ETF has a 52-week low of $60.87 and a 52-week high of $85.73. The firm has a market capitalization of $250.01 million, a price-to-earnings ratio of 20.44 and a beta of 0.71. The company has a fifty day simple moving average of $79.46 and a 200-day simple moving average of $80.49.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.